Leib E S, Restivo C, Paulus H E
Am J Med. 1979 Dec;67(6):941-7. doi: 10.1016/0002-9343(79)90634-x.
The clinical manifestations, treatment and survival of 64 patients with polyarteritis nodosa seen from 1955 to 1977 were evaluated. In general, the patients had multisystem involvement. No patient with cutaneous vasculitis alone was accepted into the study. The clinical diagnosis was confirmed by biopsy in 34 patients, by autopsy in 13 and by angiography in 10. The patients were treated at the discretion of the physicians responsible for their care. Eight of the 64 patients received only supportive therapy (group 1), 34 received corticosteroids alone (group 2), and 22 received both corticosteroids and an immunosuppressive agent (group 3). Five patients in group 2 and one patient in group 3 were excluded from survival studies because of insufficient length of therapy. Patients in the three treatment groups were very similar with respect to 18 clinical and laboratory variables. Median survival times for the three groups were three months, 63 months and 149 months, respectively; 5 year survival rates were 12 per cent, 53 per cent and 80 per cent (p less than 0.05). Despite difficulty in precisely defining polyarteritis nodosa, the data suggest a better prognosis for treated patients than has previously been appreciated, with improvement in outcome when an immunosuppressive agent is added to corticosteroid therapy.
对1955年至1977年间收治的64例结节性多动脉炎患者的临床表现、治疗及生存情况进行了评估。总体而言,患者多系统受累。仅患有皮肤血管炎的患者未纳入本研究。34例患者经活检确诊,13例经尸检确诊,10例经血管造影确诊。患者由负责其治疗的医生酌情治疗。64例患者中,8例仅接受支持性治疗(第1组),34例仅接受皮质类固醇治疗(第2组),22例接受皮质类固醇和免疫抑制剂联合治疗(第3组)。第2组中的5例患者和第3组中的1例患者因治疗时间不足被排除在生存研究之外。三个治疗组的患者在18项临床和实验室变量方面非常相似。三组的中位生存时间分别为3个月、63个月和149个月;5年生存率分别为12%、53%和80%(p<0.05)。尽管难以精确界定结节性多动脉炎,但数据表明,接受治疗的患者预后比之前认为的要好,在皮质类固醇治疗中加用免疫抑制剂可改善预后。